In a cohort of 1,117 patients presenting with PE symptoms, the median sFlt-1/PlGF level among those experiencing adverse outcomes, whether maternal (AKI, HELLP syndrome, pulmonary edema, DIC, cerebral hemorrhage, or eclampsia) or fetal, was significantly higher compared to patients without adverse outcomes (median 177 [IQR, 54–362] versus 14 [IQR, 4–62]). Here, PGF is linked to HELLP syndrome.